Cabaletta Bio, Inc. is a late-stage clinical biotechnology company based in Philadelphia that is developing targeted cell therapies designed specifically for patients with autoimmune diseases. Its lead candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-directed CAR T-cell therapy being evaluated across a broad RESET clinical program spanning rheumatology, neurology, and dermatology, including myositis, systemic lupus erythematosus and lupus nephritis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
The company's strategic focus is on delivering potentially curative, deep, and durable responses while simplifying the treatment experience through weight-based dosing, a no-preconditioning approach in select indications, and automated manufacturing through its partnership with Cellares. I follow CABA closely because it represents a differentiated play on the emerging cell-therapy-for-autoimmune-disease opportunity, with a registrational myositis study underway and a planned BLA submission for rese-cel. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the trailing 30 days, CABA shares have fallen approximately 38%, declining from a closing level of about $1.54 to roughly $0.95. The move was broadly one-directional, with only brief and short-lived rebounds, including a temporary bounce in early November that quickly faded as the stock resumed its downtrend.
The quarterly picture is even more pronounced. Roughly three months ago, the stock traded near $3.19, meaning it has declined approximately 70% over the trailing quarter. After peaking near $3.57 in early September, the shares have printed a persistent series of lower highs and lower lows, with the downtrend accelerating through October and into November as the stock crossed below the $1 mark.
The most significant development in the period was the company's third-quarter 2026 financial report, which showed a net loss of $53.1 million, up from $44.9 million a year earlier, driven by higher research and development spending tied to advancing rese-cel trials and manufacturing readiness. Although the reported EPS of -$0.28 modestly beat consensus expectations, the market appeared to focus on rising cash burn and the company's statement that additional financing will be needed to complete clinical development.
Positive clinical data released at ACR Convergence 2026 did not reverse the slide. The presentation showed that all six dermatomyositis patients maintained immunomodulator-free responses through one year and that all five lupus nephritis patients with follow-up achieved a DORIS response. Despite this, the stock continued to fall, suggesting that dilution risk, funding concerns, and broader risk-off sentiment in small-cap biotech outweighed the favorable data. The breach below $1 added further technical and psychological pressure on the shares. From what I see, this reaction highlights how financing worries can dominate even solid clinical updates in this sector.
The quarterly decline reflects a shift from optimism earlier in the year to sustained selling pressure in the second half. The stock had previously rallied on encouraging EULAR 2026 data and a $150 million financing that included participation from Eli Lilly, which strengthened the balance sheet and supported a 2H27 BLA timeline for rese-cel in myositis.
However, as the year progressed, rising operating expenses, widening losses, and the prospect of additional equity financing created an overhang on the shares. A succession of positive data readouts failed to generate durable buying, and the stock steadily gave back its earlier gains as investors re-rated the risk-reward in light of the company's cash needs and the extended timeline to a potential BLA submission in Q1 2028. This is important because it shows how quickly sentiment can shift when capital requirements come into focus.
Looking ahead, the primary catalyst for Cabaletta Bio is the RESET-Myositis registrational trial, with topline results anticipated in the second half of 2027 and a planned BLA submission in Q1 2028. The company has also indicated that go-forward development plans for preconditioning-free dosing in lupus and generalized myasthenia gravis are expected in the first half of 2027.
Investors will likely monitor the company's cash position and any additional financing activity, given management's guidance that further capital will be required. Broader factors, including the interest-rate environment, biotech risk appetite, regulatory interactions with the FDA, and manufacturing-readiness milestones with Cellares, may also influence sentiment. As with any clinical-stage biotechnology company, trial outcomes, safety data, and timing shifts remain key risks that could materially affect the stock. I’m watching this closely as the timeline to potential approval stretches out.
In my own research process, I frequently rely on Tickeron’s AI Trend Prediction Engine to cross-reference potential price movements and compare them against my fundamental views on names like CABA. This platform offers a systematic way to scan for patterns and signals across thousands of tickers, helping me stay objective when clinical-stage biotech names face volatility. It serves as a useful complement to traditional analysis without replacing personal judgment on factors like cash runway or trial timelines.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 80 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CABA turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 41 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.596). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases
Industry Biotechnology